BF 388

Drug Profile

BF 388

Latest Information Update: 09 Jul 1998

Price : $50

At a glance

  • Originator Scherer Healthcare
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Jul 1998 Biofor is now part of Scherer Healthcare
  • 28 Dec 1995 Discontinued-Preclinical for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top